{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'C. Any condition that in the opinion of the investigator, would preclude', 'participation in this study', '7. Current evidence of any of the following:', 'a. Uncontrolled hypertension', 'b. Gastrointestinal disorder affecting absorption', 'C. Active infection (e.g., human immunodeficiency virus [HIV] or viral', 'hepatitis) or other medical condition that would make', 'prednisone/prednisolone (corticosteroid) use contraindicated', 'd. Any condition that in the opinion of the investigator, would preclude', 'participation in this study', '8. The use of drugs known to lower the seizure threshold, including: atypical', 'antipsychotics (e.g., clozapine, olanzapine, risperidone, ziprasidone), bupropion,', 'lithium, meperedine, pethidine, phenothiazine antipsychotics (e.g.,', 'chlorpromazine, mesoridazine, thioridazine), and tricyclic antidepressants (e.g.,', 'amitriptyline, desipramine, doxepin, imipramine, maprotiline, mirtazapine) (see', 'Appendix C for a more complete list of prohibited concomitant medications).', '9. The use of strong CYP3A4 inhibitors, including: itraconazole, clarithromycin,', 'erythromycin, diltiazem, verapamil, delavirdine, atazanavir, indinavir,', 'nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole,', 'grapefruit juice (or grapefruits) (see Appendix C for a more complete list of', 'prohibited concomitant medications).', 'Note: If a patient is on a strong CYP3A4 inhibitor, they can be reconsidered for', 'enrollment if they can safely stop said medication. A two week or 5 half-lives,', 'whichever is longer, washout will be required prior to enrolling on study. Subject', 'may not resume medication while receiving apalutamide.', '10. Strong CYP3A4 inducers, including: phenytoin, carbamazepine, rifampin,', \"rifabutin, rifapentin, phenobarbital, efavirenz, tipranivir, St. John's wort (see\", 'Appendix C for a more complete list of prohibited concomitant medications).', '30', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'Note: If a patient is on a strong CYP3A4 inducers, they can be reconsidered for', 'enrollment if they can safely stop said medication. A two week or 5 half-lives,', 'whichever is longer, washout will be required prior to enrolling on study. Subject may', 'not resume medication while receiving apalutamide', '11. Any psychological, familial, sociological, or geographical condition that could', 'potentially interfere with compliance with the study protocol and follow-up', 'schedule.', '3.3. Inclusion of Women and Minorities', 'This study is focused on prostate cancer; therefore the treatment cohort is only', 'applicable to men. Men from all ethnic and race groups are eligible for this study.', '31', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}